Applications of aptamers in nanodelivery systems in cancer, eye and inflammatory diseases
In recent years the research in nano-based medical applications has grown extraordinarily large. Nanotechnology offers improvements in many areas of healthcare, including early detection and diagnostics, novel treatments and long-term, noninvasive imaging. Some of the technologies involve the use of a known drug, without chemical modifications, but combine or conjugate it to a nanoparticle (NP) so as to improve its targeting ability. A major area of interest is in biomolecules that specifically or preferentially target diseased cells and tissues. These molecules or ligands can be used to improve the specificity of diagnostic tests, as imaging techniques, to stop or inhibit disease cycles, and to target drugs to diseased cells or tissues. One form of these ligands is aptamers [1] . The nucleic acid aptamers are ssDNA or RNA oligonucleotides 20-80 bases long and fold into unique 3D conformations due to intramolecular interactions. These single strands of oligonucleotides are able to recognize and bind to diverse molecules, such as proteins, sugars, nucleic acids and phospholipids [2] . Owing to their ability to act as inhibitors of target proteins in a broad range of diseases aptamers are promising therapeutic agents. This inhibiting factor is due to the aptamers' ability to bind to and limit the activities of the target proteins [3, 4] . Aptamers have many advantages over antibodies [4] . For example, they can be made completely in vitro (they are selected via, but not characterized by, systematic evolution of ligands by exponential enrichment [SELEX]) [5] . They are characterized by binding assays and functional assays, are fast and cheap to produce, can be functionalized to improve efficacy of targeting, have a longer shelf life, are up to fivetimes smaller in size (allowing better penetration into tissues), have low toxicity and possess low immunogenicity [6] . Aptamers can distinguish between closely related, but nonidentical, members of a protein family or also in between the different functional and conformational states of the same protein. Cancer is a complex disease that can affect people of all ages, races and sexes. Most of the current anticancer treatments involve the use of chemotherapeutic agents that kill diseased and healthy cells. The basic principle of improving cancer therapy is to get the drug to the exact location where it is needed, at the lowest therapeutic dose, and keep it there long enough to show its effect. Inflammatory diseases are mediated by the immune system and involve many different types of immune cells. The inflammatory processes are complex and not yet fully understood. Most therapeutic approaches address one aspect of the immune response, but recent work suggests that a more general but targeted approach might work best [7] . This article will discuss the applications that aptamers have in the treatment of cancer, ocular and i nflammatory diseases.
Aptamer selection
The ability of DNA and RNA to interact with proteins was known even before the development of aptamers. However, owing to their lack of specificity in binding, a selection procedure was developed known as SELEX (Figure 1 ). This procedure requires the synthesis of large numbers of DNA and RNA oligonucleotides. The nature of nucleotides that form the aptamer determines its structure and stability [5] .
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Aptamers can be 'made' for most targets, including toxic molecules, because they are made in vitro. In 1990, independent work carried out by Ellington et al. led to the development of the first method for the selection of novel ligands from combinatorial nucleic acid libraries. This method is known as SELEX [8] . It is essentially a technique for selecting nucleic acids that bind with high specificity to target molecules. The first step is the synthesis of a very large library of oligonucleotides with random sequences of 20-80 nucleotides with fixed primer region at the 5´-and 3´-ends for PCR [6] . For the initial incubation step of the oligonucleotide sequences, the target molecule is also included. Any sequences that do not bind are removed by affinity chromatography using either biotinylated DNA aptamer on streptavidin immobilized columns [9] , or using microfluidic systems, which includes a random aptamer extraction device and a chip amplification device where the final bound sequences are amplified by PCR [10] . The process continues, but after each cycle the stringency of the affinity chromatography conditions increases to select only the tightest bound sequences. Once a sequence has been selected, the aptamer can undergo chemical modifications to reduce the length of the aptamer, to increase its specificity or to introduce amino or thiol groups attached to the 5´-or 3´-end, allowing conjugation to a nanomaterial. They can be radiolabeled or fluorescently tagged for imaging. Finally, various chemical moieties can be introduced at the 5´-or 3´-end or internally within the sugar-phosphate backbone or at the nucleobases to enhance their in vivo stability [11] . From the ssDNA pool the DNA sequences can be selected directly, whereas for an RNA aptamer, first the mRNA has to be formed by transcription from the ssDNA. Once the oligonucleotides are prepared they are exposed to the target to which they bind according to their specificity. The loosely bound ones are removed whereas the tightly bound ones are finally separated and innumerated by PCR after repeating the procedure several times (6-18 times). (B) The selection for peptide aptamer can be made using various systems, most widely used is the yeast two-hybrid system. The system utilizes a genetically engineered strain of yeast in which biosynthesis of certain nutrients (e.g., amino acids and sugar) is lacking. The protein of choice is used as a bait protein and is bound to the activation domain in a plasmid and the target protein is bound to the DNA binding domain in another plasmid. The fusion of the two proteins leads to an interaction between the two proteins and the domains, which leads to transcription of the nutrient (e.g., b-galactosidase), thus allowing the mutant yeast to grow on the b-galactosidase-deficient media [3, 11, 13, 14] . SELEX: System evolution of ligands by exponential enrichment.
future science group Applications of aptamers in nanodelivery systems in cancer, eye & inflammatory diseases Review SELEX requires repeated rounds of extraction that demands significant time and labor. Work involving capillary electrophoresis-SELEX shows that high affinity aptamers can be obtained in two rounds of selection, shortening the selection procedure. Capillary electrophoresis-SELEX selects the binding sequences based on a mobility shift induced by complex formation within the target molecule [12] . Another recent work has suggested modifications in SELEX to improve its sensitivity and specificity, such as use of automatic magnetic beads based on a microfluidic system that integrates a random ssDNA extraction device and further one chip nucleic acid amplification device for rapid screening of aptamers, which prevent loss of aptamers by manual pipetting [10] . Other recent studies also suggest an upgrade in SELEX. The generation of ssDNA plays the key role in SELEX. Purity and yield of ssDNA can affect the success of each application, thus instead of this method a study was performed for the strand separation by using l-exonuclease digestion, which was proved to be considerably beneficial for in vitro selection of DNA aptamers [13] . DNA aptamers are guanosine-thymidine rich and usually have the octet and hairpin loop structure, the RNA aptamers are capable of adopting a wider range of structures, such as asymetric loops and tetraloops among others [14] . On the other hand, the protein aptamers are proteins designed to interfere with other protein interactions inside the cell. They consist of variable peptide loops attached at both ends to a protein scaffold. The variable loops are 10-20 amino acids long and the scaffold is a protein of good solubility and compacity properties. The selection of a peptide aptamer is mostly carried out by employing the yeast two-hybrid systems, where the protein of choice and the target protein are incorporated in two different plasmids that fuse together, leading to an interaction between the two proteins. The final shape of the aptamer is determined by amino acid composition and scaffold protein [15] .
Target delivery
Development of well-tailored nanocarriers has potentiated the delivery of aptamers at specific target sites. Core-shell NPs, quantum dots (QDs), micelle type NPs, polyethyleneimine (PEI), lipopolysaccharides and other types of release molecules have been employed for this purpose. To enhance the selectivity and sensitivity of aptamers they are conjugated to NPs. This has been demonstrated in a recent study where aptamers with a dissociation constant in the nanomolar range were coupled to magnetic NPs. As such, aptamers are conjugated to NPs to enhance the aptamer's selectivity and sensitivity, which offers a highly sensitive method for detecting cancer cells [16] . Conjugation of aptamers with NPs depends on the kind of NPs being used, for example N-hydroxysuccinimide activated polyethyleneimine-polyethylene glycol (PEI-PEG) when reacted directly with 5´-NH 2 modified aptamer shows a covalent linkage between the aptamer and the PEI-PEG complex [17, 18] . The same mechanism is followed for polylactic acid-PEG complex with aptamers [19, 20] . However, conjugation between gold NPs (AuNPs) and aptamer (the 5´-thiol modified aptamer in disulphide form, protected by a mercaptohexanol group), which reacts directly with the AuNPs, shows attachment of both mercaptohexanol group and oligo S groups on the surface of the AuNPs, indicating a surface interaction [21, 22] . Other examples of conjugation with an active drug compound and chitosan molecule by ionic gelation method were also reported [23, 24] . Covalent bonding between bufalin and polyvinyl alcohol-associated lipid NPs [24] and covalent linkage of aptamer against polylactide NPs containing cyanine dyes were also reported [19] . The mechanism of targeting drug conjugated with aptamer and NP and its delivery into the specific target site and finally the cross-sectioning and visualization of individual cells to study the effect of drug is illustrated in (Figure 2 ) [25] .
Conjugation of nanomaterials and aptamers for biosensing and diagnostics primarily uses fluorescence-based sensors (e.g., QDs and AuNPs). It is carried out either by a label method (chemical labeling) or by a label-free method (different absorption properties of ssDNA and dsDNA) [17] . There are many forms of SELEX currently in use, and while their fundamentals are the same, the aptamer sequence identified can be used for very specific needs. For example, the cell-SELEX method can be used when an aptamer is required to bind specifically to a target cell (Figure 1 ). This method produces an aptamer that can be conjugated to a nanomaterial that will preferentially target diseased cells over normal cells. The cell-SELEX method may also produce aptamer ligands that can improve the delivery of NPs to intracellular components. An aptamer could be made to escape from the endosome and therefore prevent degradation and increase NP delivery [5] . Recent work in this area has yielded a group of aptamers specific to T cells from lymphoblastic leukemia [26] . The aptamers were fluorescently future science group Review Kanwar, Mohan, Kanwar, Roy & Bawa labeled and confirmed to have been internalized by the leukemia T cells. This work will be discussed further in the next section. Aptamers can be designed to release the NPs they are conjugated to at a time when a 'release molecule' is added, which changes the conformational structure of the aptamer (as suggested by the work carried out on surface enhanced Raman scattering [17] ). One of the most successful applications of aptamers has been the formation of aptamers that bind to VEGF [27] . This is a protein involved in angiogenesis. Angiogenesis is the formation of new blood vessels. This aptamer treatment has US FDA approval for use as an intraocular injection for treating age-related macular degeneration. Clinical studies showed that angiogenesis was reduced due to the inhibition of VEGF (Table 1) . This is a favorable characteristic of aptamers; what they bind to, they usually inhibit. It removes the need for toxic treatments [27] [28] [29] [30] . An example of target delivery includes the aptamer that recognizes prostate-specific membrane antigen (PSMA); the aptamer binds to malignant cells over expressing it and delivers the anticancer drug. Kim et al. were successfully able to explain the aptamer-specific targeting in prostate cancer cells expressing PSMA receptors on the surface by the use of PEI-PEG polyplex and shRNA-PEI-PEG-aptamer-doxorubicin complex was able to suppress prostate cancer [20] .
Pastor et al. also demonstrated that aptamer for PSMA is targeted into tumor cells by help of PSMA aptamer-siRNA conjugate and shows better tumor suppression than the cancer vaccination GVAX [31] . In another study, PEG was conjugated with an aptamer that binds to PSMA on prostate cancer cells and it was proven that it is efficiently taken up by the prostate cancer cells, showing target delivery [32] . Aptamers are used for drug discovery but they themselves can act as therapeutic drugs. Preclinical stages of many aptamers are completed, some are in the phases of the clinical trial and few are already available in the market. The therapeutic potential of aptamers is their ability to inhibit the function of the protein due to their specific 3D structure, which shows high affinity binding to the target proteins. Mucin 1 (MUC1) is a large, rod-like glycoprotein The aptamer binds to the NPs by covalent or surface linkages, whereas the drug encapsulates within the nanocarrier or attaches to its surface to form the aptamer-drug-NP conjugate. There are different routes of administration, such as intravenous injections [31] and oral delivery [18, 25] . Due to systemic transfer of the conjugate nanocarriers it localizes in the liver and also in the kidney in small amounts [25] . Since aptamer have high affinity towards the target molecule, the major portion of conjugate nanocarriers internalize to the target site. Finally, the drug is released from the nanocarrier into the target cell where it activates or deactivates the specific pathways in order to show its effect. NP: Nanoparticle.
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Applications of aptamers in nanodelivery systems in cancer, eye & inflammatory diseases Review that is widely expressed on normal epithelial tissues. However, when they become malignant, its expression is increased at least tenfold. The selection of high-affinity and high-specificity DNA aptamers against the highly immunogenic epitome of the unglycosylated protein core of the MUC1 glycoprotein has been carried out [33] . The NF-kB DNA aptamer has been evaluated in several animal models. These molecules hold great importance in the drug delivery system and hence in the success of therapeutic drug delivery [34] . As shown in Table 1 other such markers for which the aptamers have been evaluated include, transcription factor (TCF)-1 binding RNA aptamer [35] and PDGF receptor binding DNA aptamer [36] .
Aptamers & cancer
It is highly unlikely for any person to not know someone whose life has been touched by cancer. As such, the constant push towards novel cancer therapies is undaunted by the prospect 5 bG40 RNA Boron-containing molecules Brain, skin cancer and rheumatoid arthritis [3] 6 CD4-specific aptamer 14 RNA Antigen-presenting cells Immunosuppressant [3] 7 DD7, ED1, ED45 RNA hNE-specific ligand Anti-inflammatory [3] 8 Del 60 tetramer RNA T-cell surface receptor Cancer immunotherapy [3] 9 EGFR-binding aptamer RNA EGFR Nanoparticle delivery [4] 10 IGEL1.2 and D17.4 RNA, DNA Human IgE Antiallergic response [3] 11 Ligand 1.1 RNA, DNA HIV-1 RT Anti-HIV [3] 12 LD201t1 DNA L-selectin Anti-inflammatory action [3] 13 MUC1-binding aptamer DNA MUC1 Breast, pancreatic and ovarian cancer targeting [33] 14 NF-kB-binding aptamer RNA NF-kB Target transcriptase in many diseases [34] 15 2′-NH 2 -30-ligand RNA IFN-a Anti-inflammatory, immunoregulatory [3] 16 PSMA-binding aptamer RNA PSMA Prostate cancer diagnosis and therapy [4] 17 PDGF/PDGFR-binding aptamer DNA PDGFR Improve transport of drugs to tumors and brain [36] 18 PTK7-binding aptamer DNA PTK7 Chemotherapeutic drug delivery [4] 19 SE RNA RNA Hepatitis C virus NS3 helicase domain Viral proliferation in chronic hepatitis, liver cirrhosis and hepatocellular carcinoma [3] 20 Spiegelmers NOX 2149 and NOX 2137a/b RNA ORL-1R Decrease in pain and stress [3] 21 SU6668 RNA SU6668 blocks PDGFR Important for pericyte-endothelial interactions [3] 22 SU5416 RNA VEGF receptor Inhibition of tumor growth [3] 23 Tenascin-C-binding aptamer RNA Tenascin-C Brain cancer detection [4] 24 TCF-1-binding aptamer RNA TCF-1 Colon cancer growth inhibition [35] Review Kanwar, Mohan, Kanwar, Roy & Bawa that very soon, cancer will be the number one cause of death in the western world [37] . One aspect of cancer that is being explored for cancer therapy and detection is tumor markers; these are substances whose concentration is elevated in the blood, urine, or body fluids or tissues in cancer patients. There are many different tumor markers, each indicative of a particular disease process, and they are used in oncology to help detect the presence of cancer. An elevated level of a tumor marker can indicate cancer; however, there can also be other causes. Tumor markers can be expressed directly by the tumor or by nontumor cells as a response to the presence of a tumor [38] . Aptamers have opened up a new field for the use of these tumor markers, resulting in more efficient and better targeted treatments represented in the list of aptamers (DNA/ RNA), their specific targets and their mode of action (Table 1) . Conjugation of aptamers to NPs can give rise to more efficient and specifically targeted therapeutic agents. One such example of this is a NP-aptamer conjugate that targets PSMA. This aptamer formulation has proven successful in reducing tumor size after a single dose in preclinical studies [39] .
Another example is an aptamer-doxorubicin (apt-dox) conjugate for use in T cells of lymphoblastic leukemia [26] . This study demonstrated that the apt-dox conjugate specifically targeted and killed the T cells along with low toxicity to nontarget cells. The study also showed that the apt-dox was internalized in the target cells. Dox is a very common anticancer drug, but it does have toxic side effects. The apt-dox formulation has shown reduced toxic effects due to the acid-labile link connecting them that allows the dox to be released by the acidic environment in endosomes. Other studies have demonstrated that dox conjugates can be less potent than the free dox. Conversely, this study demonstrates that apt-dox is just as potent as free dox due to the high affinity of the aptamer and its very efficient internalization into the target cells. This study also compared how selective the apt-dox conjugate was in killing efficiency by comparing two different cell lines via flow cytometry and cytotoxic assays. The apt-dox displayed higher toxicity than the other dox conjugate, although there was some variability due to differences in response to the cell lines. The next step of this study is to investigate the antitumor capabilities using human tumor grafts in mice. The potential for targeted drug delivery using aptamers has a wide-reaching appeal for other types of cancers [26] . In a recent work, polyamido amine dendrimers were used to modify QDs and improve their solubility in aqueous solution, then the modified QDs were conjugated with DNA aptamer GBI-10, which can recognize extracellular matrix protein tenascin-C on the surface of human g lioblastoma cells [40] .
Aptamers as nanosensors in cancer diagnosis
In recent years, the synthesis of a wide variety of NPs like metallic NPs, such as QDs, magnetic NPs, silicon NPs and carbon nanotubes, has led to their use as biosensors. Integration of aptamer and NPs is a new trend in forming a hybrid sensing system for molecular level recognition [41] . Some examples of the aptamer-NP hybrids used for detection of small analytes include: Apt-AuNPs, and Apt-AuNPs and DNAzyme for mercury (Hg 2+ by colorimetric detection [42] ; AuNPs and Dye-Apt for Hg 2+ by fluorescence detection [43] ; Apt-AuNPs for potassium K + by colorimetric detection; and Apt-AuNPs and DNAzyme for lead (Pb 2+ ) by colorimetric detection [42] . Aptamer nanosensors can be focused on monitoring toxic metal ions, such as Pb2 + , Hg2 + and K + [44] .
Lead can cause renal malfunction and inhibition of brain development. Mercury can damage brain, heart and kidneys, and potassium can cause muscle cramps, paralysis, changes in heart rhythms and dehydration [45] . Aptamer nanosensors have also been used for detection of analytes, such as adenosine, cocaine, ATP, AMP and cysteine [44, 45] . The best way to increase the efficiency and reduce toxicity of cancer drugs is to direct the drugs to the required target and to keep the drug there for the required amount of time for therapeutic action to take place, such as use of PEG-coated aptamer NPs to target PSMA in prostate cancer cells [20] . In another study, liposomes were used to deliver aptamers to tumors to make them more sensitive to chemotherapy agents. These aptamers blocked the production of the a-folate receptor, thereby decreasing cell survival of breast cancer cell lines, making the cell line five-times more sensitive to dox. This is a good example of how nanotechnology is improving the effectiveness of known drugs to lower dosages and reduce toxic effects by better conjugation with harmless nanocarriers [46] . Bagalkot et al. [47] have identified a multifunctional NP that can be used for targeting, imaging and therapeutics. The fluorescence resonance energy transfer based nanoprobe is a QD conjugated to an aptamer, which is conjugated to dox. The energy transfer occurs future science group
Applications of aptamers in nanodelivery systems in cancer, eye & inflammatory diseases Review between the dox and the QD. The aptamer was conjugated to the surface of the QD and dox was conjugated to the aptamer by noncovalent intercalation. The QD-apt-dox conjugate can bind to the PSMA expressed from cancer cells and release dox over time. Other modes of imaging are MRI using crosslinked dextran iron oxide [48] and electrochemical detection by measuring the changes in redox states of redox active probes, including cadmium sulfate, lead sulfate and platinum NPs, among others. This can be used in targeted drug delivery in cells using aptamer-NP conjugates for cancer imaging and therapy, anthracycline drugs and prostate cancer [17] . An existing technology that aptamers have found their way into is the thermal destruction of tumors. Thermal ablation is an existing technique, but with the inclusion of aptamer targeting technology it may be able to be used more effectively. Previously, this technique has only been used for low-lying tumors owing to the inability to target the tumors in order to minimize damage to the normal surrounding tissue. In order to overcome this problem gold nanoshells are being used. The shells are made up of a silica core surrounded by a thin film of gold. The metal will heat up when the appropriate wavelength of light is directed at it. Aptamers for a protein in the target cells are developed and conjugated to the surface of the gold nanoshells. These aptamers directly target the tumor cells. After injection the particles are allowed to migrate to the area and accumulate in the tumors due to the 'leaky' nature of tumor tissues. Since, normal cells and tissues do not display this leaky nature, the NPs do not accumulate in these normal tissues. A near-infrared laser is used to heat up the tumor (containing the NPs) to destroy the tumor [49] .
Inflammatory diseases
Lack of immunogenicity in aptamers makes them an excellent potential agent in therapeutic approaches against autoimmune disorders. Inflammation is a defensive reaction of the body's tissues to disease or damage. It may be acute or chronic, and symptoms include heat, swelling, redness and pain. Chronic inflammatory diseases affect millions of people worldwide, inflicting suffering, economic stress and even premature death. Some of the most debilitating include rheumatoid arthritis, osteoarthritis and multiple sclerosis (MS). In these diseases the natural process of inflammation, which is normally initiated to repair tissue and fight infection, has malfunctioned, attacking the CNS and musculoskeletal system [50] . Although many inflammatory diseases have some sort of genetic influence, some are initiated by other means. Cytokines are naturally produced proteins that trigger inflammatory and disease fighting responses to toxins, injury, bacteria and viruses. These proteins are of particular interest when studying, treating and preventing inflammatory diseases. In MS, the disease attacks random areas of the CNS white matter, causing the destruction of the insulation of nerve fibers and the spinal cord, termed myelin. Studies show that cytokines may cause abnormal autoimmune response and can cause myelin damage. Normal MS therapy includes corticosteroids to suppress the immune system, but now MS sufferers have a choice of new biologically based anti-inflammatory treatments [51] .
One of the most common drugs used to treat cancer is diclofenac (DCF). It is a non steroidal anti-inflammatory drug with analgesic, antiinflammatory and antipyretic properties. It works by blocking cyclooxgenase to inhibit prostaglandin synthesis. DCF is also used for treatment of degenerative joint diseases and other arthritic conditions. Although they are effective, their long-term use is limited by side effects, including heart attack, gastrointestinal lesions, headache, dizziness, skin rashes, edema, and hepatic and renal damage [52] . Detection of DCF is mostly by high performance liquid chromatography; however, new aptamer-based biosensors are being used to detect the target molecule. The aptamers are conjugated to the surface of an activated amine metal NP. This technique can be used to capture unused DCF in the body. It can also be used to capture DCF from body fluids and from unused treatments as DCF is known to be an environmental pollutant [52] . Recent work has been carried out on monocyte chemoattractant protein-1 (MCP-1). It has been identified as an initiator or mediator in inflammatory diseases and atherosclerosis. Its role is to recruit a number of immune cells, including T cells, NK cells and monocytes. MCP-1 has been found at high levels in the joints of rheumatoid arthritis sufferers, in asthmatics and in atherosclerotic lesions in humans. The aim of this work was to reduce the activity of MCP-1. The SELEX method was used to produce aptamer sequences that would bind to mouse MCP-1. Two sequences were tested, ADR7 and ADR22. Aptamer binding, aptamer inhibition, effect of aptamers on MCP-1 signaling and aptamer inhibition of chemotaxis were assays performed to evaluate and compare the sequences. Results from the heparin inhibition future science group Review Kanwar, Mohan, Kanwar, Roy & Bawa binding assay showed that both aptamers inhibited heparin when tested against mouse MCP-1. Interestingly, only the ADR22 aptamer was able to inhibit heparin binding when tested against human MCP-1. This is one of the key features of RNA aptamers -they can distinguish between closely related proteins. The authors also suggested that modifications could be made to the aptamer to improve the binding affinity [53] . One suggestion was to conjugate the aptamer to PEG in order to decrease its rate of clearance from the blood. Another was to conjugate the aptamer to fluorescein or biotin for in vitro diagnostic use, or to conjugate the aptamer to a chelating agent for in vivo imaging. Other autoimmune disorders for which aptamers have been established are myasthenia gravis, systemic lupus erythematosus and oncostatin M, which is a member of the IL-6 cytokine family that has been identified as a key inflammatory modulator of the chronic inflammatory disease rheumatoid arthritis and L-selectin [6] .
Eye diseases
Analysis of population-based data collected from 55 countries by the WHO revealed that approximately 37 million people are blind and 124 million people have low vision [54] . This study also revealed that corneal scarring is the third leading cause of global blindness followed by cataract and glaucoma [55] . Numerous factors, such as viral, bacterial, fungal infections, trauma, physical, mechanical or surgical injuries, are known to cause corneal scarring and/or angiogenesis [56] . The precise molecular mechanism causing these corneal disorders is still unclear; nonetheless, disturbances in normal wound healing have been shown to play a key role [56] [57] [58] . A cascade of cytokines and chemokines has been shown to participate in this process. Among many cytokines, TGF-b and VEGF have been shown to cause scarring and angiogenesis in the cornea, respectively [58, 59] . During corneal angiogenesis new blood vessels start appearing and migrating towards the clear cornea, reducing its clarity and transparency. The potential of aptamers to treat corneal scarring and angiogenesis has been examined by many researchers [27] [28] [29] [30] 60] . The potency of TGF-b antibody to reduce scarring [40] and VEGF antibody to control corneal angiogenesis [61] has been reported in the literature. In addition, many other aptamers, such as Avastin ® , bevacizumab, RNA-oligonucleotide pegaptanib (Macugen ® ), antisense nucleotide against insulin receptor substrate-1, VEGF-A antibody, vasostatin, diquafosol tetra sodium, and plasminogene kringle 5, have been evaluated to treat angiogenesis in the eye [27-30 , 59-64] . The results of these studies show remarkable reduction in ocular angiogenesis due to the inhibition in VEGF activity. Pegaptanib sodium is the first aptamer approved by the US FDA as a therapeutic agent to treat ocular neovascularization in patients in America [65] . Many other aptamers are in various stages of clinical trials for treating ocular angiogenesis.
Conclusion
Aptamers have many properties that make them attractive for use in clinical applications, including diagnostic, imaging and therapeutics. Since aptamers are very specific and sensitive they can be immobilized for preparing cancer targetspecific NPs in cancer-specific drug delivery and for better imaging systems in cancer patients. Magnetic NPs can be used to monitor the cancer load in these patients by specific delivery in cancer cells. It is the ability of the aptamer to inhibit the activity of the molecule to which it has bound that has the most use in terms of therapeutics (in most of the described aptamer-targeted drug delivery, no inhibition of activity is involved). Other favorable properties include the complete synthetic route for production, their small size for greater tissue penetration, low toxicity and immunogenicity, which makes them suitable for chronic use. The high affinity and specificity with which they bind to their targets makes it possible to distinguish between very closely related target molecules. Aptamers have also found favor in targeted nanodelivery systems. Owing to their high affinity and specificity for a target, aptamers can be conjugated to a wide range of therapeutic agents. Since the aptamer has been selected for a specific molecule, the therapeutic agent will be targeted directly. This minimizes toxic effects to other cells, increases bioavailability and reduces the doses required. Aptamers have unique properties compared with other molecules, such as antibodies, meaning they have a special role to play in medical treatments. Inflammatory diseases and cancer are the two areas where aptamers have found success. As more is discovered about aptamers and their uses, their contribution to medicine may be pivotal in not only treating, but curing some of the world's greatest medical challenges.
Future perspective
The basic principle of any therapy is to target the site and distribute the drug where it is needed the most. Aptamers are small in size future science group Applications of aptamers in nanodelivery systems in cancer, eye & inflammatory diseases Review and cheap to produce with high specificity and longer shelf life. Moreover, aptamers have low immuno genicity, thus opening up the possibility of noninvasive delivery of drugs that target cancer, ocular and inflammatory diseases. Owing to establishment of various biomarkers and antigens present on the surface of cancer cells or inflammatory cells, aptamers can be readily developed and specifically targeted with the help of nanocarriers, which possess enhanced efficiency in binding affinity and show good chemical conjugation. Thus, aptamers can be used for diagnosis as well as monitoring the effect of treatments. Aptamer technology has many expectations and is used for several applications, including its role as biosensors, and has been proven to be a successful therapy against cancer. Conjugation of aptamers with nano carriers and drugs/siRNA holds the key to great success in the future of disease-targeted therapy and improved diagnosis. 
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Executive summary
Aptamers have a longer shelf life, are smaller in size, have low immunogenicity and improve efficacy of targeting. System evolution of ligands by exponential enrichment employs a wide range of techniques, such as use of columns, microfluidic systems and capillary electrophoresis, for selection of aptamers against a specific target. DNA aptamers are more stable than RNA aptamers, whereas RNA aptamers have a wide range of structures and protein aptamers have good solubility. Nanocarriers have potentiated the delivery of aptamers at specific target sites. Conjugation mechanisms between aptamers and nanocarriers include covalent bonding and surface adsorption. Aptamer-doxorubicin conjugates show higher internalization in target sites due to high affinity of aptamers. Polyamidoamine dendrimer-modified quantum dots, when conjugated with DNA aptamer, can recognize tenascin-C on glioblastoma cells. Fluorescence resonance energy transfer, MRI and redox probes were used for improved diagnosis with specific aptamer imaging systems. Aptamer-conjugated nanocarriers have been used for detection of anticancer and anti-inflammatory drugs. Aptamers play an important role in reduction of initiators or mediators of inflammatory diseases. 
